Psychoactive Pharmacotherapy for Posttraumatic Stress Disorder
Summary
Posttraumatic stress disorder (PTSD) is a complex psychiatric condition arising after exposure to life-threatening events, marked by intrusive memories, avoidance, negative cognitions and hyperarousal. First-line pharmacotherapy typically comprises selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), which target monoamine systems yet achieve full remission in fewer than one in three patients. Adjunctive agents such as alpha-1 blockers (for nightmares) and atypical antipsychotics (for comorbid agitation) are prescribed off-label but carry risks of metabolic and neurological side effects. Emerging approaches focus on modulation of glutamatergic transmission and neuroplasticity to accelerate symptom relief and bolster resilience. N-methyl-D-aspartate (NMDA) receptor antagonists, notably intravenous ketamine, have demonstrated rapid reduction in core PTSD symptoms and may facilitate fear extinction by altering synaptic plasticity in the prefrontal cortex and amygdala. Compounds that disrupt memory reconsolidation or enhance extinction—such as 3,4-methylenedioxy-methamphetamine (MDMA) in conjunction with psychotherapy—are undergoing controlled trials, aiming to integrate pharmacological and behavioural interventions. Cannabinoid receptor modulators and agents acting on corticotropin-releasing factor pathways represent additional experimental avenues. Current research is refining dosage, timing and delivery to optimise therapeutic windows, minimise adverse effects and personalise treatments according to individual neurobiological profiles. Advances in neuroimaging and biomarkers seek to predict response and guide combination strategies, emphasising global applicability across diverse health-care settings.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Psychoactive Pharmacotherapy for Posttraumatic Stress Disorder publication trend
The graph below shows the total number of articles in psychoactive pharmacotherapy for posttraumatic stress disorder across all publications each year (not limited to Nature Index journals).
Technical terms
Selective serotonin reuptake inhibitor (SSRI): A class of antidepressants that increases serotonin availability by blocking its reabsorption into presynaptic neurons.
Serotonin-noradrenaline reuptake inhibitor (SNRI): An antidepressant class that inhibits the reuptake of both serotonin and noradrenaline, enhancing mood and arousal regulation.
NMDA receptor antagonist: A compound that blocks N-methyl-D-aspartate glutamate receptors, modulating synaptic plasticity and facilitating rapid symptom relief in stress-related disorders.
Fear extinction: A learning process in which conditioned fear responses decrease through repeated safe exposure to trauma-related cues, forming the basis for exposure-based therapies.
References
- PTSD: from neurobiology to pharmacological treatments. European Journal of Psychotraumatology (2016).
- Effects of subanesthetic intravenous ketamine infusion on neuroplasticity-related proteins in the prefrontal cortex, amygdala, and hippocampus of Sprague-Dawley rats. IBRO Neuroscience Reports (2019).
- Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression. European Neuropsychopharmacology (2024).
- The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis. Frontiers in Psychiatry (2022).
- A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD. Frontiers in Psychiatry (2019).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.